News Releases

Webcast
Q1 2018 Surmodics, Inc. Earnings Conference Call
Thursday, February 8, 2018 7:30 AM CST
Date Title Teaser
11/08/17
Summary ToggleSurmodics Reports Fourth Quarter Fiscal 2017 Results and Provides Fiscal 2018 Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Nov. 8, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 fourth quarter, ended September 30, 2017 and financial outlook for
10/26/17
Summary ToggleSurmodics to Present at Canaccord Genuity Medical Technologies and Diagnostics Forum Webcast is Live on Thursday, November 9 , at 9 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 26, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and
10/26/17
Summary ToggleSurmodics to Webcast Fourth Quarter 2017 Earnings Conference Call on November 8 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 26, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its fourth quarter 2017
10/23/17
Summary ToggleSurmodics Announces First Patient Enrolled in TRANSCEND Pivotal Clinical Trial for SurVeil® Drug-Coated Balloon Comparing SurVeil ® DCB to Medtronic IN.PACT ® Admiral ® DCB Plan to enroll up to 446 patients at approximately 78 sites EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Oct. 23, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies, today announced
09/18/17
Summary ToggleSurmodics Announces Global Approvals of .014" Low-Profile PTA Balloon Dilation Catheter The company received FDA 510(k) and CE Mark clearance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 18, 2017-- Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced it has received U.S.
09/13/17
Summary ToggleSix-Month Data from the Surmodics SurVeil® Drug-Coated Balloon Early Feasibility Study Presented at VIVA 2017 Study met primary endpoint and six-month secondary safety endpoints Results demonstrated primary patency of 100% and significant improvement in measured clinical outcomes EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Sep. 13, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and
08/03/17
Summary ToggleSurmodics Reports Third Quarter Fiscal 2017 Results and Updates Fiscal 2017 Guidance EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Aug. 3, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 third quarter, ended June 30, 2017.
07/26/17
Summary ToggleSurmodics Receives IDE Approval to Initiate Pivotal Trial of the SurVeil™ Drug-Coated Balloon Study compares SurVeil™ DCB to Medtronic IN.PACT® Admiral® DCB SurVeil DCB design includes new proprietary coating for interventional treatment of PAD EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Jul. 26, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic
07/25/17
Summary ToggleSurmodics to Webcast Third Quarter 2017 Earnings Conference Call on August 3 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jul. 25, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its third quarter fiscal
05/22/17
Summary ToggleSurmodics to Present at Upcoming Investor Conferences EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--May 22, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and chief executive officer, and Andy LaFrence , vice president
04/27/17
Summary ToggleSurmodics Reports Second Quarter Fiscal 2017 Results, Updates Fiscal 2017 Financial Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 27, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced results for its fiscal 2017 second quarter, ended March 31, 2017 .
04/18/17
Summary ToggleSurmodics to Webcast Second Quarter 2017 Earnings Conference Call on April 27 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 18, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its second quarter
04/17/17
Summary ToggleSurmodics Appoints Lisa Wipperman Heine to Its Board of Directors EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Apr. 17, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced the addition of Lisa Wipperman Heine to the Company’s Board of Directors, effective on April
03/14/17
Summary ToggleSurmodics to Present at Oppenheimer Healthcare Conference Webcast is Live on Tuesday, March 21 , at 10:55 a.m. (ET) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Mar. 14, 2017-- Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that Gary Maharaj , president and
02/09/17
Summary ToggleSurmodics Announces 2017 Annual Shareholders Meeting Virtual Meeting on February 14 at 4:00 p.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 9, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that its virtual Annual Meeting of
02/02/17
Summary ToggleSurmodics Reports First Quarter Fiscal 2017 Results GAAP Revenue of $17.8 Million , up 7%; Medical Device increase 12% GAAP EPS of $0.17 , Non-GAAP EPS of $0.19 Raises Revenue and EPS Guidance EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Feb. 2, 2017-- Surmodics, Inc. (Nasdaq:SRDX), a leading provider of medical device and in vitro diagnostic technologies
01/24/17
Summary ToggleSurmodics to Webcast First Quarter 2017 Earnings Conference Call on February 2 Webcast is Live at 7:30 a.m. (CT) EDEN PRAIRIE, Minn. --(BUSINESS WIRE)--Jan. 24, 2017-- Surmodics, Inc. (Nasdaq: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, today announced that it will host a live webcast of its first quarter fiscal